LCAR-HL30 cells

Phase 1Recruiting

0 views this week 0 watching💤 Quiet

Interest: 30/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hodgkin's Lymphoma

Conditions

Hodgkin's Lymphoma, Anaplastic Large Cell Lymphoma

Trial Timeline

Jul 1, 2024 → Aug 1, 2028

NCT ID

NCT06494371

About LCAR-HL30 cells

LCAR-HL30 cells is a phase 1 stage product being developed by Legend Biotech for Hodgkin's Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06494371. Target conditions include Hodgkin's Lymphoma, Anaplastic Large Cell Lymphoma.

What happened to similar drugs?

4 of 20 similar drugs in Hodgkin's Lymphoma were approved

Approved (4) Terminated (4) Active (12)

❌Nivolumab + Brentuximab vedotinOno PharmaceuticalPhase 3

🔄R-mabHDI and ABVD + ABVDEli LillyPhase 3

🔄Bortezomib + Rituximab + RituximabJohnson & JohnsonPhase 3

🔄Zoledronic Acid + Vitamin D + Calcium CarbonateNovartisPhase 3

❌Ofatumumab + Rituximab + Ofatumumab + RituximabNovartisPhase 3

🔄Panobinostat + PlaceboNovartisPhase 3

🔄rituximab [MabThera/Rituxan] + Standard chemotherapyRochePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06494371	Phase 1	Recruiting	Jul 1, 2024	Aug 1, 2028	Hodgkin's Lymphoma

Competing Products

20 competing products in Hodgkin's Lymphoma

See all competitors

Product	Company	Stage	Hype Score
YM155 + Rituximab	Astellas Pharma	Phase 2	35
Tazemetostat	Eisai	Phase 2	35
ONTAK	Eisai	Phase 2	35
Tazemetostat	Eisai	Phase 1	29
ME-401	Kyowa Kirin	Phase 1	29
ME-401	Kyowa Kirin	Phase 2	39
Nivolumab + Brentuximab vedotin	Ono Pharmaceutical	Phase 3	32
R-mabHDI and ABVD + ABVD	Eli Lilly	Phase 3	36
Prednisone + Vinblastine + Doxorubicin (Adriamycin) + Gemcitabine	Eli Lilly	Phase 1/2	32
gemcitabine	Eli Lilly	Phase 2	27
gemcitabine + cisplatin + dexamethasone	Eli Lilly	Phase 2	35
R-mabHD + ABVD	Eli Lilly	Phase 2	31
LY317615	Eli Lilly	Phase 2	35
LY4584180 + Rituximab	Eli Lilly	Phase 1	36
Bortezomib + Rituximab + Rituximab	Johnson & Johnson	Phase 3	40
HRS-3738	Jiangsu Hengrui Medicine	Phase 1	25
SHR1459 ；YY-20394 + SHR1459 ；YY-20394 + Gemcitabine-Oxaliplatin	Jiangsu Hengrui Medicine	Phase 2	31
ABT-199 + Ketoconazole	AbbVie	Phase 1	29
ABT-199 + Rifampin	AbbVie	Phase 1	21
[14C]ABT-199 (GDC-0199)	AbbVie	Phase 1	21